This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With significant progress made in researchers’ understanding of dermatological diseases, a pathway has been made for the development of targeted vaccines, according to data published in Vaccines. 5 Throughout the past 10 years, development of vaccines for preventing skin diseases has made significant progress.
The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.
2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.
With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. Whole foods contain a mixture of micronutrients, fiber, antioxidants, and other compounds that augment the absorption and application of essential vitamins and minerals.
Viral hepatitis poses a significant risk to HIV patients, with overlapping transmission modes complicating diagnosis and treatment, highlighting the need for targeted support and vaccination. What we know is that this is compounded and accelerated in people living with HIV.”
READ MORE: Q&A: Myths, Misinformation Surrounding Hepatitis Vaccines The study cohort included 283 patients 12 years of age or older with an acute HCV Infection who were treatment-naïve. Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting Gretchen K.
The introduction of the human papillomavirus (HPV) vaccine marked a major turning point, contributing to nearly a 50% reduction in incidence rates and a 70% decrease in mortality since the 1950s.
How will RFK Jr’s American dream for vaccines play out? The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed.
The financing round was co-led by Kurma Partners , WE Life Sciences , and the French Tech Seed Fund managed by Bpifrance , on behalf of the French government, under the France 2030 initiative. Additional participants included Argobio , Angelini Ventures , CARMA Fund , Capital Grand Est , and Sambrinvest.
The study authors noted that an estimated 1 billion individuals are expected to have obesity by 2030. Obesity is defined as a body mass index (BMI) of 30.0 and higher. Rumore, PharmD, Esq, MS, LLM, FAPhA July 18th 2025 A Novel Agent, Incretin Mimetics, and Potential Pharmacologicals for the Management of MASH Hongxiang Zhao Maria A.
A report by Azoth Analytics expects that globally, the single-use technology rocking bioreactors market will grow at a compound annual growth rate (CAGR) of 3.9 percent between 2025 and 2030. The report noted that last year, the cell culture sector held approximately 60 percent of the single-use technology rocking bioreactors market.
million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.
The possibility of additional funding comes at a time replete with investor uncertainty as a result of ongoing financial instability in the market, which has been compounded by the collapse of Silicon Valley Bank (SVB) and Credit Suisse. billion) by 2030. The UK government also has its own plans for funding research. billion ($18.2
Examples include platforms as small as autonomous units placed within a facility and mobile production trailers for compounding to platforms as large as a prefabricated, self-contained GMP facility. Worldwide Modular Facilities in Pharmaceutical and Biotechnology Industry to 2030 - Impact Analysis of COVID-19.” 13 July 2021.
The World Health Organization (WHO) 2021 roadmap outlines plans to eradicate 20 listed diseases, which include leprosy, scabies and mycetoma, by 2030. Neglected tropical diseases are a major global health concern, affecting over 1.7 billion people, many of whom live in the poorest and most vulnerable communities.
Worldwide, more than 700,000 people die by suicide annually and the WHO has set a target to reduce suicides by one third by 2030. The problems for community pharmacists can be compounded by the lack of suitable referral pathways and the fact that patients do not always understand why the pharmacist is asking questions.
of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.
The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7 LXE408 is currently entering Phase II clinical development.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content